Andreas Sommer

Title: Innovations of Andreas Sommer in Therapeutic Proteins

Introduction

Andreas Sommer is a notable inventor based in Boulder, Colorado, recognized for his contributions to the field of therapeutic proteins. He holds a total of four patents, focusing on high molecular weight human angiogenic basic fibroblast growth factors. His work has significant implications for medical science, particularly in the areas of angiogenesis and tissue repair.

Latest Patents

Sommer's latest patents include innovative methods for producing high molecular weight forms of therapeutic proteins. These single-polypeptide-chain proteins maintain similar therapeutic activities as their native counterparts. Specifically, his patents detail high molecular weight forms of the human basic fibroblast growth factor (bFGF), which exhibit activities such as mitogenic, chemotactic, angiogenic, and neurotrophic activities. The high molecular weight angiogenic factors are produced through DNA translation that initiates at non-ATG codons, incorporating additional polypeptide sequences N-terminal to the human bFGF factor. His patents also describe methods for isolating these factors from human hepatoma cell lines and producing them using recombinant DNA techniques.

Career Highlights

Throughout his career, Sommer has worked with prominent organizations, including Synergen, Inc. and New York University. His experience in these institutions has allowed him to advance his research and contribute to the scientific community significantly.

Collaborations

Some of his notable coworkers include David A. Moscatelli and Daniel B. Rifkin, who have collaborated with him on various projects related to his research in therapeutic proteins.

Conclusion

Andreas Sommer's innovative work in the field of therapeutic proteins has paved the way for advancements in medical treatments and therapies. His patents reflect a deep understanding of protein biology and its applications in health science.